Abstract: A sheet-shaped cell culture is disclosed that includes myocardial cells derived from pluripotent stem cells and has excellent functional properties. A sheet-shaped cell culture obtained by culturing a cell population that includes myocardial cells derived from pluripotent stem cells, wherein the proportion of the number of the myocardial cells derived from pluripotent stem cells to the total number of cells in the cell population is 50% to 70%; a method of producing the sheet-shaped cell culture; a composition including the sheet-shaped cell culture; and a method of treating a disease using the sheet-shaped cell culture or the composition.
Type:
Grant
Filed:
May 12, 2017
Date of Patent:
September 21, 2021
Assignees:
TERUMO KABUSHIKI KAISHA, OSAKA UNIVERSITY
Abstract: The present invention relates to methods for the specific separation of target cells from a biological sample, comprising specific binding of the target cells to phase-change hydrogel compositions and separation of respective cell-hydrogel complexes by counter-current centrifugation.
Abstract: The invention relates generally to the fields of biology and life sciences. More particularly, the invention relates to compositions and methods for modulating cellular physiology and pathological processing using a combination of compounds that can be found in morselized amniotic membrane tissue and morselized umbilical cord tissue preparations.
Abstract: A composition comprising lactic bacteria for use in the preventive and/or curative treatment of bacterial infections, which cause urinary tract and/or bladder inflammations is described. The composition is in particular for the treatment of recurrent cystitis.
Abstract: Provided herein are compositions and kits including a pathogen-inactivated cryoprecipitate suitable for infusion into a subject at least 1 day after thawing. The methods are useful in the efficient preparation of cryoprecipitates with desirable characteristics, including pathogen-inactivated cryoprecipitates that are suitable for infusion into a subject at least 1 day after thawing.
Type:
Grant
Filed:
June 24, 2016
Date of Patent:
August 24, 2021
Assignee:
Cerus Corporation
Inventors:
Laurence Corash, Elan Weiner, Melody Holtan, Richard Benjamin
Abstract: Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food.
Abstract: Disclosed herein are methods, compositions, kits, and agents useful for inducing ? cell maturation, and isolated populations of SC-? cells for use in various applications, such as cell therapy.
Type:
Grant
Filed:
July 21, 2020
Date of Patent:
August 3, 2021
Assignee:
President and Fellows of Harvard College
Inventors:
Quinn P. Peterson, Felicia J. Pagliuca, Douglas A. Melton, Jeffrey R. Millman, Michael Saris Segel, Mads Gurtler
Abstract: The invention provides methods, compositions and kits for making and using pericyte-like cells or perivascular stromal cells derived from pPS cells.
Type:
Grant
Filed:
February 18, 2015
Date of Patent:
August 3, 2021
Assignee:
ReCyte Therapeutics, Inc.
Inventors:
Jiwei Yang, Dana Larocca, Midori Greenwood-Goodwin
Abstract: The invention provides purified mammalian hybrid hepatocyte (HybHP) cells, compositions comprising HybHP cells, methods for purifying HybHP cells, methods for in vitro culture of HybHP cells, and methods for using HybHP cells to repopulate and/or treat the liver of a subject in need thereof.
Type:
Grant
Filed:
May 3, 2016
Date of Patent:
July 20, 2021
Assignee:
The Regents of the University of California
Abstract: Disclosed herein are compositions, devices, and methods that provide cellular materials in ready to use formats for experimental, therapeutic, and tissue engineering protocols. For example, compositions containing frozen or non-frozen cell present as aggregates are disclosed. Also disclosed a compositions containing cellular materials that after storage are suitable for dispersion, e.g. by 3D printing. Also disclosed is a kit for producing bioink compositions. Also disclosed is a closed system device comprising a cell material composition described herein.
Abstract: Disclosed are methods for isolating endothelial progenitor cells (EPC). More particularly, the present invention discloses methods for isolating endothelial progenitor cells that exhibit self-renewal and differentiation capacity. The isolated cellular population of the present invention is useful in a wide range of clinical and research setting including inter alia, the in vitro or in vivo generation of endothelial cells and the therapeutic or prophylactic treatment of a range of conditions via the administration of these cells. Also facilitated is the isolation of endothelial progenitor cells for research purposes such as in vitro based screening systems for testing the therapeutic impact and/or toxicity of potential treatment or culture regimes to which these cells may be exposed to. The present invention also discloses methods for isolating mesenchymal stem cells, in particular mesenchymal stem cells of fetal and/or maternal origin.
Type:
Grant
Filed:
November 9, 2018
Date of Patent:
June 29, 2021
Assignee:
The University of Queensland
Inventors:
Jatin Patel, Paul Kiarash Khosrotehrani, Nicholas Maxwell Fisk
Abstract: A process for producing a bone construct, including the steps of providing a perfusion bioreactor having an inlet and an outlet; providing the perfusion bioreactor with a seeded scaffold comprising a porous scaffold seeded with mesenchymal stem cells; continuously perfusing the seeded scaffold with an osteogenic induction (differentiation) media; measuring dissolved oxygen content of the osteogenic induction media at the inlet and at the outlet to determine an oxygen uptake rate (OUR) for the seeded scaffold; measuring glucose content of the osteogenic induction media to determine a glucose consumption rate (GCR) for the seeded scaffold; and removing the seeded scaffold from the perfusion reactor as a bone construct after the ratio of the OUR to the GCR (OUR/GCR) has been determined to exceed a predetermined threshold OUR/GCR value.
Type:
Grant
Filed:
August 13, 2018
Date of Patent:
June 29, 2021
Assignee:
The Board of Regents of the University of Oklahoma
Abstract: The present invention provides a method for preparing nicotinamide mononucleotide (NMN) by bioanalysis. The method includes a step of catalytically reacting a plurality of raw materials including nicotinamide, ATP, and ribose in the presence of nicotinamide phosphoribosyltransferase (Nampt), ribose phosphate pyrophosphokinase, and ribokinase, to prepare the NMN.
Abstract: Disclosed herein are human hepatocytes for example isolated human hepatic progenitor cells, artificial tissue or organ thereof, and kits or compositions thereof. Also disclosed herein are various methods of using a human hepatocyte disclosed herein.
Type:
Grant
Filed:
July 24, 2020
Date of Patent:
June 8, 2021
Assignee:
ACCELERATED BIOSCIENCES CORP.
Inventors:
Jau-Nan Lee, Tony Tung-Yin Lee, Yuta Lee, Eing-Mei Tsai
Abstract: Provided herein is an isolated decelluarized amniotic membrane (DCM) and methods for using same therapeutically in vivo and in vitro. In one aspect, the isolated DCM is further processed, freezing, freeze drying, lyophilization micronized into powder or treatment with pepsin to create a hydrogel.
Type:
Grant
Filed:
April 15, 2016
Date of Patent:
June 8, 2021
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Volodymyr Ryzhuk, Aijun Wang, Diana Farmer, Benjamin Keller
Abstract: The present disclosure relates to an apparatus and a method for manufacturing a channel-coupled scaffold. The present disclosure provides a method for manufacturing a channel-coupled scaffold, which includes: (1) a step of compressing a first elastic substrate which includes a groove on the surface of the substrate to close the groove; (2) a step of loading a scaffold composition onto the closed groove; and (3) a step of restoring the elastic substrate. The present disclosure also provides an apparatus for manufacturing a channel-coupled scaffold, which includes: a first elastic substrate which includes a groove on the surface of the substrate and onto which a scaffold composition is loaded: and a compression module which compresses the width of the groove of the elastic substrate to close it. The apparatus or method may accumulate a microchannel controlling local mass transfer, and align a collagen fiber in the scaffold at the same time.
Type:
Grant
Filed:
February 21, 2017
Date of Patent:
June 1, 2021
Assignee:
Korea Institute of Science and Technology
Inventors:
Nakwon Choi, Sohyun Kim, Sohyeon Jeong, Eui Sung Yoon, Changjoon Justin Lee, Il-Joo Cho
Abstract: The present invention relates to: Podoviridae bacteriophage Vib-PAP-2 (accession number KCTC 12910BP) which has the capability to specifically destroy Vibrio parahaemolyticus, is characterized by having a genome represented by SEQ ID NO: 1, and is isolated from nature; and a method for preventing and treating Vibrio parahaemolyticus infections, using a composition containing bacteriophage Vib-PAP-2 as an active ingredient.
Type:
Grant
Filed:
November 10, 2016
Date of Patent:
June 1, 2021
Assignee:
INTRON BIOTECHNOLOGY, INC.
Inventors:
Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Soon Hye Hwang, Sang Hyeon Kang
Abstract: Disclosed are methods and systems for the quantification of AngI and/or determination of plasma renin activity in a sample. The methods and systems disclosed herein can be useful for diagnosis of hypertension, aldosteronism and other abnormalities of the renin angiotensin aldosterone system (RAAS).
Type:
Grant
Filed:
November 17, 2017
Date of Patent:
May 18, 2021
Assignee:
Laboratory Corporation of America Holdings
Inventors:
William O. Slade, Jr., Russell Philip Grant, Christopher Michael Shuford
Abstract: Cells derived from postpartum placenta and methods for their isolation are provided by the invention. The invention further provides cultures and compositions of the placenta-derived cells. The placenta-derived cells of the invention have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications.
Type:
Grant
Filed:
March 4, 2019
Date of Patent:
May 11, 2021
Assignee:
DePuy Synthes Products, Inc.
Inventors:
Anthony J. Kihm, Ian R. Harris, Sanjay Mistry, Alexander M. Harmon, Darin J. Messina, Agnieszka Seyda, Chin-Feng Yi, Anna Gosiewska
Abstract: A composition comprising lactic bacteria for use in the preventive and/or curative treatment of bacterial infections, which cause urinary tract and/or bladder inflammations is described. The composition is in particular for the treatment of recurrent cystitis.